#4 MI OF IOTA VALUE SOFTWARE#

The calculation of the sample size was determined by our statistical team. Written informed consent was obtained from each participant. This research was approved by the institutional review board (IRB No. This prospective pilot study was performed at a single institute (Samsung Medical Center, Seoul, Korea) between 28 March and 19 July 2019.

The aim of this study is to compare the IOTA-ADNEX model with gynecologic experts in differentiating benign and malignant ovary diseases. Our hypothesis is that the IOTA-ADNEX model is not different from the subjective analysis of experienced experts in differentiating benign and malignant ovary disease. However, there were rare prospective studies comparing this model and gynecologic experts in terms of characterizing ovary tumors. Through various external validation studies, the discriminating performance of ovarian tumors with the IOTA-ADNEX model has been better than other existing models. This model uses three clinical features and six US features to predict the malignancy risk of adnexal masses. In 2014, a new model with better performance, the assessment of different neoplasias in the adnexa (ADNEX) model, was developed in this group. The IOTA group demonstrated that these predictive models have better diagnostic performance than preexisting systems. Since 2005, the international ovarian tumor analysis (IOTA) group has presented other risk predictive models with logistic regression (LR1, LR2) and sonographic characteristics (simple rules). Several scoring models, such as the risk of malignancy index (RMI) and the risk of ovarian malignancy algorithm (ROMA), have been developed for the differentiation of adnexal masses. This may provide the patient with the most optimal follow-up or treatment with the most benefit at the least cost. However, the 5-year overall survival in early-stage cancer is as high as 92.4%, and thus early detection using US improves a patient’s survival rate. Most patients with ovarian cancer are diagnosed at an advanced stage, with a below-30% 5-year survival rate. Second, ovarian malignancy is not so common among gynecologic tumors, but it is a fatal disease with high recurrence rates. First, precise differentiation of benign and malignant tumors helps clinicians to know what to do: observation or surgery, a surgery type, laparotomy or laparoscopy or other additional studies, tumor marker, computed tomography (CT), or magnetic resonance imaging (MRI). There are two important reasons to use US examination in differentiating ovarian tumors from benign to malignancy. Gynecologic ultrasonography (US) is a useful tool for identifying the presence of ovarian mass, differentiating between benign and malignant tumors, and determining the treatment plan of ovarian tumors.

#4 MI OF IOTA VALUE SOFTWARE#

Subsequently, being familiar with this US software may help gynecologic beginners to reduce unnecessary surgery. (4) Conclusions: The IOTA-ADNEX model is equal to gynecologic US experts in excluding benign ovarian tumors.

The optimal cut-off point using the ADNEX model was 47.3%, with a specificity of 0.977 (95% CI: 0.880–0.999). The area under the ROC curve of the ADNEX model (0.924) was not significantly different from that of subjective assessment (0.953 in all participants, 0.951 in the surgical group p = 0.391 in all participants, p = 0.407 in the surgical group). The specificity of the ADNEX model was 0.816 (95% confidence interval (CI): 0.680–0.912) in all participants and 0.795 (95% CI, 0.647–0.902) in the surgical group. Benign and malignant diseases were confirmed in 49 (83.1%) and 10 (16.9%) participants, respectively. (3) Results: Fifty-nine participants were eligible: 54 and 5 underwent surgery and follow-up computed tomography (CT), respectively. The optimal cut-off value of the ADNEX model for excluding benign diseases was calculated. Receiver operating characteristic (ROC) curves were also generated to compare overall accuracies. (2) Methods: All participants in this prospective study underwent ultrasonography (US) equipped with the IOTA-ADNEX TM model and subjective assessment by a sonographic expert. (1) Background: The aim of this study is to compare the IOTA-ADNEX (international ovarian tumor analysis–assessment of different neoplasias in the adnexa) model with gynecologic experts in differentiating ovarian diseases.

4 mi of iota value